Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Remote ischemic conditioning (RIC) has been proven to improve neurologic function after stroke in RICAMIS trial. Aggravated thrombosis and inflammatory through interaction between platelet and immune cells affected the prognosis of stroke. We conducted an exploratory secondary analysis of RICAMIS to investigate whether platelet-to-neutrophil ratio (PNR) predicted efficacy of RIC in stroke.

Methods: Patients without protocol violation and with baseline blood routine examination from the full analysis set were included and divided into low PNR and high PNR subgroups. The primary outcome was 90-day excellent functional outcome defined as modified Rankin Scale score of 0-1. Compared with usual care alone, we investigated efficacy of RIC treatment in each PNR subgroup and their interaction.

Results: Of 1679 patients, 360 were assigned to low PNR and 1319 into high PNR. Compared with usual care alone, RIC treatment was associated with higher likelihood of 90-day excellent functional outcome across PNR, but significantly different in low PNR (60.9% versus 50.3%, adjusted RD, 11.3%; 95% CI, 1.1% to 21.5%; P =0.03) and not significantly different in high PNR (70.8% versus 65.3%, adjusted RD, 3.9%; 95% CI, -1.2% to 8.9%; P =0.13). No significant interaction was found (P =0.96).

Conclusions: This study firstly investigated the association between PNR at admission and efficacy of RIC treatment in stroke. With respect to long-term functional outcomes, patients benefited from RIC treatment regardless of PNR, but the benefit increased when level of PNR at admission was lower. Trial registration ClinicalTrials.gov Identifier: NCT03740971.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12225825PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0322037PLOS

Publication Analysis

Top Keywords

ric treatment
16
pnr
12
efficacy ric
12
low pnr
12
high pnr
12
platelet-to-neutrophil ratio
8
remote ischemic
8
ischemic conditioning
8
90-day excellent
8
excellent functional
8

Similar Publications

Background: Remote ischemic conditioning (RIC), a novel neuroprotective therapy, has broad potential for reducing the occurrence and recurrence of cerebrovascular events, yet its mechanisms are not incompletely understood. The aim of this study is to investigate whether RIC alleviates apoptosis, inflammation, and reperfusion injury in rat models of ischemic stroke by regulating the Elabela (ELA)-apelin-Apelin receptor (APJ) system.

Methods: We established a rat model of middle cerebral artery occlusion (MCAO) with ischemia-reperfusion injury, and RIC was administered twice daily for 3 days post-MCAO.

View Article and Find Full Text PDF

Remote ischemic conditioning (RIC) is a simple, non-invasive procedure that has been shown to be safe and feasible in multiple smaller clinical trials. Recent large randomized controlled trials have yielded mixed results regarding clinical effect. Patients with severe stroke may experience greater benefit from cerebroprotective interventions, highlighting the need for adjunctive therapies to enhance endovascular therapy (EVT) outcomes.

View Article and Find Full Text PDF

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).

Ann Dermatol Venereol

September 2025

Université Grenoble Alpes, Service de dermatologie, Centre Hospitalier Universitaire, Grenoble, France; UGA/Inserm U 1209/CNRS UMR 5309 Joint Research Center, Institute for Advanced Biosciences, 38700 La Tronche, France.

Background: COVID-19 pandemic had a variable impact on the severity of melanomas.

Objective: To assess the role of the COVID-19 pandemic in France on the severity of melanomas at initial diagnosis.

Methods: New melanoma cases recorded in the French RIC-Mel database were included in a retrospective study spanning three timeframes: pre-COVID (01/01/2018 to 03/16/2020), lockdown (03/17/2020 to 10/05/2020), and the COVID pandemic period (hereafter referred to as "COVID") (11/05/2020 to 30/09/2022).

View Article and Find Full Text PDF

Public and philanthropic research funding, publications, and research networks for cancer in the Commonwealth and globally between 2016 and 2023: a comparative analysis.

Lancet Oncol

September 2025

School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Fred N Binka School of Public Health, University of Health and Allied Sciences, Volta Region, Ghana; School of Medicine, University for Development Studies, Tamale, Ghana.

This Review presents a comprehensive analysis of the amounts and distribution of public and philanthropic global cancer research funding between 2016 and 2023, including patterns of international collaboration and downstream research output, with an emphasis on the Commonwealth. We show that annual investment decreased globally each year, apart from a rise in 2021. Network analysis revealed that grant and publication collaborations between the Commonwealth, the USA, and the EU are facilitated by linkages through a core group of Commonwealth countries, including the UK, Australia, and Canada.

View Article and Find Full Text PDF

Background: Parkinson's disease (PD), the most prevalent neurodegenerative disorder, affects over 7.5 million individuals worldwide and imposes a substantial financial burden. Exercise (EXE) has demonstrated efficacy in improving motor symptoms of PD; however, its application is limited by motor symptoms such as bradykinesia, rigidity, gait instability, and fatigue, which reduce patient tolerance and adherence.

View Article and Find Full Text PDF